Immune Checkpoint Blockade Therapy
Immune checkpoints are accessory molecules that either promote or inhibit T cell activation. Two inhibitory molecules, cytotoxic T cell antigen 4 (CTLA-4) and programmed death 1 (PD-1), got high attention, as inhibition of CTLA-4 or PD-1 signaling provides the first immune therapy that significantly improves the survival of patients with metastatic solid cancers. Inhibition of CTLA-4 or PD-1 was first studied in and approved for patients with metastatic melanoma. Blocking immune checkpoints is also efficient in non-small-cell lung cancer, renal cell cancers, hypermutated gastro-intestinal cancers and others.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Thomas Wieder, Thomas Eigentler, Ellen Brenner, Dipl Biol, Martin R öcken Source Type: research
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Gastroenterology | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer